Leerink partners maintained a Buy rating on Gossamer Bio stock on August 19, 2025, citing strategic partnerships and potential benefits from Trump-era tariffs.
1 report, 1 independent
Updated Aug 19
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Leerink partners maintained a Buy rating on Gossamer Bio stock on August 19, 2025, citing strategic partnerships and potential benefits from Trump-era tariffs.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Gossamer Bio (United States)
company in San Diego, United States
Nothing else this week.
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
-
Leerink partners
U.S. investment bank
Related events
Coverage
Newest first; wire copies grouped- Insider MonkeyH.C. Wainwright and Leerink Partners Reiterate ‘Buy’ Ratings on Gossamer Bio, Inc. (GOSS) With significant hedge fund interest and a share price under $10, Gossamer Bio, Inc. (NASDAQ:GOSS) secures a